PE20010781A1 - Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion - Google Patents

Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion

Info

Publication number
PE20010781A1
PE20010781A1 PE2000001110A PE0011102000A PE20010781A1 PE 20010781 A1 PE20010781 A1 PE 20010781A1 PE 2000001110 A PE2000001110 A PE 2000001110A PE 0011102000 A PE0011102000 A PE 0011102000A PE 20010781 A1 PE20010781 A1 PE 20010781A1
Authority
PE
Peru
Prior art keywords
imidazol
naftil
ethanol
substituted
tumors
Prior art date
Application number
PE2000001110A
Other languages
English (en)
Inventor
Akihiro Tasaka
Akio Ojida
Tomohiro Kaku
Masami Kusaka
Masuo Yamaoka
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20010781A1 publication Critical patent/PE20010781A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE NAFTALENO DE FORMULA I, R ES H, UN GRUPO PROTECTOR; R1 ES ALQUILO; R2 ES UN GRUPO 1, 2, 3; EL ANILLO A1 TIENE DE 5-6 MIEMBROS CON UN O; EL ANILLO B1 TIENE DE 5-6 MIEMBROS CON UN O; R3 Y R5 SON H, ALQUILO, OH, TIOL, AMINO, ACILO, HALOGENO, R4 ES UN HIDROCARBURO AROMATICO, HETEROCICLO, CARBAMOILO; R6 ES ALQUILO; n ES 0-3. SON COMPUESTOS PREFERIDOS 6-[1-HIDROXI-1-(1H-IMIDAZOL-4-IL)-2-METILPROPIL]-N-METIL-2-NAFTAMIDA; 6-[1-HIDROXI-1-(1H-IMIDAZOL-4-IL)-2-METILPROPILO]-N-ISOPROPIL-2-NAFTAMIDA, N-CICLOPROPIL-6-[1-HIDROXI-1-(1H-IMIDAZOL-4-IL)-2-METILPROPIL]-2-NAFTAMIDA, ENTRE OTROS. EL COMPUESTO I ES UN INHIBIDOR DE LIASA C17,20 ESTEROIDE, ES UN AGENTE ANTITUMOR, REDUCTOR DE ANDROGENO, Y PUEDE SER UTIL PARA TRATAR EL CANCER DE PECHO, PROSTATA
PE2000001110A 1999-10-22 2000-10-18 Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion PE20010781A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30155699 1999-10-22
JP2000189728 2000-06-20

Publications (1)

Publication Number Publication Date
PE20010781A1 true PE20010781A1 (es) 2001-08-08

Family

ID=26562739

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001110A PE20010781A1 (es) 1999-10-22 2000-10-18 Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion

Country Status (9)

Country Link
US (1) US6649643B1 (es)
EP (1) EP1222174B1 (es)
AT (1) ATE432263T1 (es)
AU (1) AU7950000A (es)
CA (1) CA2387869A1 (es)
CO (1) CO5251418A1 (es)
DE (1) DE60042274D1 (es)
PE (1) PE20010781A1 (es)
WO (1) WO2001030762A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229408B1 (hu) * 2000-11-17 2013-12-30 Takeda Pharmaceutical Új imidazol-származékok és eljárás elõállításukra
WO2002040470A1 (fr) * 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Derives de l'imidazole, leur procede de preparation et leur application
MXPA06000401A (es) * 2003-07-10 2006-03-17 Osi Pharm Inc Derivados de naftileno como inhibidores de citocromo p450.
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
AU2007209380B2 (en) * 2006-01-27 2011-12-08 F. Hoffmann-La Roche Ag Use of 4-imidazole derivatives for CNS disorders
CN101528710B (zh) 2006-10-19 2012-11-07 弗·哈夫曼-拉罗切有限公司 氨基甲基-4-咪唑类
EP2086959B1 (en) 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
CN101535298A (zh) 2006-11-16 2009-09-16 弗·哈夫曼-拉罗切有限公司 取代的4-咪唑类化合物
CN101557810B (zh) 2006-12-13 2012-11-21 弗·哈夫曼-拉罗切有限公司 作为痕量胺相关受体（taar）的配体的新的2-咪唑类
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
UA98951C2 (ru) 2007-02-02 2012-07-10 Ф. Хоффманн-Ля Рош Аг 2-аминооксазолины и лекарственное средство, которое их содержит
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
AU2008270445A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (TAARs)
WO2009003867A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
EP2205239A2 (en) * 2007-10-29 2010-07-14 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
MX2013014009A (es) 2011-06-15 2014-03-12 Takeda Pharmaceutical Metodo de produccion de derivados de imidazol.
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar
CN105884691B (zh) * 2016-06-02 2017-08-25 江苏恒瑞医药股份有限公司 一种制备右美托咪定及其中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA854400B (en) 1984-06-18 1987-02-25 Lilly Co Eli 4(5)-substituted imidazoles
FI112942B3 (fi) 1991-02-21 2012-03-13 Daiichi Sankyo Co Ltd Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
US5807880A (en) 1993-09-30 1998-09-15 Yamanouchi Pharmaceutical Co., Ltd. Azole derivative and pharmaceutical composition thereof
CN1177350A (zh) 1995-03-01 1998-03-25 山之内制药株式会社 咪唑衍生物及其药学组合物
AU3534699A (en) 1998-04-23 1999-11-08 Takeda Chemical Industries Ltd. Naphthalene derivatives, their production and use
AU5566400A (en) 1999-06-22 2001-01-09 Takeda Chemical Industries Ltd. Process for the preparation of imidazole derivatives
DE60026725T2 (de) 1999-10-22 2006-09-07 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von optisch aktiven naphthalinderivaten und darin eingesetzte optische resolver

Also Published As

Publication number Publication date
CO5251418A1 (es) 2003-02-28
WO2001030762A1 (en) 2001-05-03
DE60042274D1 (de) 2009-07-09
AU7950000A (en) 2001-05-08
ATE432263T1 (de) 2009-06-15
CA2387869A1 (en) 2001-05-03
EP1222174B1 (en) 2009-05-27
EP1222174A1 (en) 2002-07-17
US6649643B1 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
PE20010781A1 (es) Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
WO2002022576A3 (en) 3-substituted indole carbohydrazides useful as cell proliferation and angiogenesis inhibitors
DE60309667D1 (de) Biphenylderivate und ihre verwendung als antiandrogene
ATE420644T1 (de) Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
BRPI0413305A (pt) compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1)
TR200103787T1 (tr) Hücre-dışı sinyal ayarlı kinazların(ERK) inhibitörü olarak yararlı pirazol bileşimler
TR199802269T2 (xx) Endotelin resept�r antagonistleri olarak faydal� indol t�revleri.
PL368109A1 (en) 2-iminopyrrolidine derivates
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
RS20050974A (en) Heterocyclically substituted pentanol derivatives,method for the production thereof,and use thereof as anti- inflammatory agents
NO20002316L (no) Additiver til inhibering av gasshydratdannelse
NO990788L (no) Ikke-peptid bombesin-reseptor-antagonister
DE60307856D1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
BR0116166A (pt) Inibidores da serina protease
BR0109512A (pt) Imidazopiridinas tricìclicas
GB2390719A (en) Theft prevention using location determination
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
NO20015892D0 (no) Inhibitorer av metallproteinaser
EE04703B1 (et) Migreeni kordumise ärahoimine
NO20031745L (no) Inhibisjon av vekstfaktoravhengigheten til tumorceller
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
ATE223928T1 (de) Azole peptidomimetische verbindungen als thrombin rezeptor antagoniste
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
ORITAN et al. and Biological Evaluation of Indole Derivatives. II ‘

Legal Events

Date Code Title Description
FD Application declared void or lapsed